Definition

A preparation of T lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) targeting immunoglobulin-beta (Igb), with potential immunostimulating and antineoplastic activities. Upon administration, the anti-Igb CAR T cells are directed to, specifically bind to, and induce selective toxicity in Igb antigen-expressing tumor cells.